ERBB2 and breast cancer: An example showing VSV-G glycoprotein can be modified to express Her2/Neu antigens, allowing selective targeting of large mammary tumors in murine models, inducing strong anti-Her2 CD8+ T cell responses and complete tumor regression [24].